Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/21752
Full metadata record
DC FieldValueLanguage
dc.contributor.authorEllis, Colin A-
dc.contributor.authorPetrovski, Slavé-
dc.contributor.authorBerkovic, Samuel F-
dc.date2019-09-04-
dc.date.accessioned2019-09-16T04:32:24Z-
dc.date.available2019-09-16T04:32:24Z-
dc.date.issued2020-01-
dc.identifier.citationThe Lancet. Neurology 2019; 19(1): 93-100-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/21752-
dc.description.abstractGenomics now has an increasingly important role in neurology clinics. Regarding the epilepsies, innovations centred around technology, analytics, and collaboration have led to remarkable progress in gene discovery and have revealed the diverse array of genetic mechanisms and neurobiological pathways that contribute to these disorders. The new genomic era can present a challenge to clinicians, who now find themselves asked to interpret and apply genetic data to their daily management of patients with epilepsy. Navigation of this new era will require genetic literacy and familiarity with research advances in epilepsy genetics. Genetic epilepsy diagnoses now directly affect clinical care, and their importance will only increase as new targeted treatments continue to emerge. At the same time, new genetic insights challenge us to move from a deterministic view of genetic changes to a more nuanced appreciation of genetic risk within complex neurobiological systems that give rise to epilepsy.-
dc.language.isoeng-
dc.titleEpilepsy genetics: clinical impacts and biological insights.-
dc.typeJournal Articleen_US
dc.identifier.journaltitleThe Lancet. Neurology-
dc.identifier.affiliationDepartment of Neurology, University of Pennsylvania, Philadelphia, PA, USAen
dc.identifier.affiliationEpilepsy Research Centre, Department of Medicine, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationCentre for Genomics Research, Discovery Sciences, Research and Development Biopharmaceuticals, AstraZeneca, Cambridge, UKen
dc.identifier.doi10.1016/S1474-4422(19)30269-8-
dc.type.contentTexten_US
dc.identifier.orcid0000-0002-1527-961X-
dc.identifier.orcid0000-0003-4580-841X-
dc.identifier.pubmedid31494011-
dc.type.austinJournal Article-
dc.type.austinReview-
local.name.researcherBerkovic, Samuel F
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairetypeJournal Article-
crisitem.author.deptEpilepsy Research Centre-
crisitem.author.deptNeurology-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

34
checked on Mar 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.